Puregon, 900 mea cartridge 1.08 ml, complete with 9 needles. 1 pack.

Puregon has a follicle-stimulating effect.

Puregon compensates FSH deficiency. It regulates normal growth and maturation of follicles, synthesis of sex steroid hormones.

Indications

Female infertility due to anovulation (including polycystic ovary syndrome, refractory to clomiphene citrate); conducting assisted reproduction programs, incl. in vitro fertilization (to induce superovulation).

Pharmacological effect

Puregon has a follicle-stimulating effect.

Replenishes FSH deficiency. Regulates the normal growth and maturation of follicles, the synthesis of sex steroid hormones.

Active ingredient

Follitropin beta

Composition

Active ingredient:

follitropin beta

Pregnancy

Contraindicated during pregnancy.

Lactating women should stop breastfeeding.

Contraindications

Hypersensitivity, tumors of the ovaries, breast, uterus, pituitary gland or hypothalamus, primary ovarian insufficiency, ovarian cysts or ovarian enlargement not associated with polycystic ovary syndrome, abnormal genital anatomy or uterine fibroids incompatible with pregnancy.

Side Effects

Ovarian hyperstimulation (abdominal pain, nausea, diarrhea, enlargement of the ovaries and their cysts, rarely – rupture of ovarian cysts, ascites, hydrothorax, weight gain); at the injection site – swelling, pain, redness, itching.

After ovulation induction, the risk of developing multiple pregnancies increases, and with in vitro fertilization, an ectopic pregnancy.

Storage conditions

In a place protected from light, at a temperature of 2–8 °C (do not freeze)

Shelf life

3 years

Manufacturer

Vetter Pharma-Fertigung GmbH and Co. KG, Germany